The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0312318 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Huanbing Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Institute of Pathogenic Biology, Hengyang Medical College, University o…. Hauptthemen laut MEDLINE: Mice, Inbred BALB C, Lacticaseibacillus rhamnosus, Probiotics, Mycoplasma pneumoniae. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Hunan Province of China.
Abstract (Originalsprache)
Mycoplasma pneumoniae represents one of the significant etiologies of community-acquired pneumonia in pediatric patients. However, clinical treatment of M . pneumoniae infection in children has encountered challenges due to the escalating resistance to quinolones. Numerous studies have highlighted the potential of probiotic lactobacillus administration in boosting immune responses to bacterial and viral respiratory infections. In this study, the protective efficacy of pre-oral administration of Lacticaseibacillus rhamnosus GG (LGG), Limosilactobacillus reuteri F275, Lactiplantibacillus plantarum NCIMB 8826, L . plantarum S1 or L . plantarum S2 was evaluated in the BALB/c mice model; it was observed that among these five strains of lactobacillus, the supplementation of LGG exhibited the most significant protective effect against M . pneumoniae infection. Moreover, when administered orally, both live LGG and heat-inactivated LGG have demonstrated efficacy in reducing the burden of M . pneumoniae in the lungs and alleviating pulmonary inflammation. Oral supplementation with LGG resulted in the inhibition of neutrophil recruitment into the lungs and increased recruitment of alveolar macrophages in M . pneumoniae -infected mice. Additionally, LGG supplementation led to increased production of IL-10 and secretory IgA (sIgA), while suppressing the levels of IL-1β, IL-6, IL-17A, and TNF-α in the lungs of mice infected with M . pneumoniae . The data suggests that supplementation with LGG can modulate immune responses, decrease pathogen load, and alleviate inflammatory injury in the lungs of M . pneumoniae -infected mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, Hunan, People's Republic of China.
ORCID-Profile: Cuiming Zhu
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Hunan Province of China
Zitieren
APA
Long, H., He, G., He, J., Du, T. F., Feng, P., & Zhu, C. (2024). The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0312318
Vancouver
Long H, He G, He J, Du TF, Feng P, Zhu C. The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice. PLOS ONE. 2024. doi:10.1371/journal.pone.0312318
BibTeX
@article{Long2024,
author = {Long, Huanbing and He, Guiting and He, Jiarong and Du, Ting Feng and Feng, Pengxiao and Zhu, Cuiming},
title = {The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0312318}
}
EUVIMED